Business Wire

Water Operators Enabled to Cut CO2e Emissions by 2.8 Million Metric Tons, Using Xylem Technology

15.5.2023 14:30:00 EEST | Business Wire | Press release

Share

Global water technology company Xylem (NYSE: XYL) delivered significant progress towards its Sustainability Goals in 2022, including enabling water utilities to reduce their CO2e emissions by 2.8 million metric tons since 2019. Through its operations, supplier and sector-wide partnerships, and green finance offerings, Xylem aims to advance water security by reducing greenhouse gas (GHG) emissions, building watershed stewardship and resilience to climate change, and advancing equitable access to Water, Sanitation and Hygiene (WASH).

The results, captured in Xylem’s latest Sustainability Report, saw the company achieve its 2025 CO2e emissions reduction goal well ahead of schedule. The reduction was enabled by the deployment of high-efficiency technologies and digital solutions. Xylem also made notable progress in reducing its own emissions, with Scope 1 and Scope 2 emissions down 21% year-on-year, while also continuing to make strides on water and waste footprint reductions across its operations.

“The stakes have never been higher in our work to tackle the world’s water challenges,” Patrick Decker, President and CEO of Xylem, said. “As impacts from climate change intensify, water operators in utilities and businesses are leaning in to be part of the solution – embracing advanced technologies that improve the resiliency and sustainability of water systems at an affordable cost – all while lowering carbon emissions.”

“Our latest Sustainability Report captures the impact of this team effort. In partnership with our customers and communities, we are working towards making the water sector a leader in climate change mitigation while solving the world’s toughest water challenges,” Decker added.

With 2022 marking another record-setting year of severe weather events, Xylem also expanded its humanitarian support. As part of the Xylem Watermark program, employees volunteered 157,000 hours to address water, sustainability, and community challenges, an increase of 39% on 2021. The program’s initiatives included providing vital aid to communities in Ukraine and to earthquake-affected regions of Turkey.

“In 2022, we were proud to partner with our customers to support their exceptional strides towards creating more modern, resilient, and environmentally sensitive water systems,” said Claudia Toussaint, Xylem’s Chief People and Sustainability Officer. “The vision of our customers and the ingenuity and diversity of our teams have been instrumental in achieving these results. It allows us to look to the future with renewed optimism and ambition.”

Other key highlights detailed in the Sustainability Report include:

  • Executed a $1 billion credit facility that ties fees and interest rates to sustainability-related performance indicators, including emissions reduction.
  • Reduced total process water use by 26% since 2019 and moved 12 of its 22 major facilities to 100% process water recycling and reuse.
  • 88% of the electricity used at Xylem manufacturing, office, and service facilities came from renewable sources in 2022, an increase of 13% from 2021.
  • Onboarded over 600 suppliers to the WASH4Work pledge and included supply partners in community WASH projects since 2019.
  • Leveraged Xylem technology, solutions, and partnerships to mobilize aid for 30 areas impacted by disaster.
  • Provided WASH solutions to communities in need, reaching more than 2.4 million people.
  • Engaged 11,800 students through Xylem Ignite, the company’s youth program, with events including the Global Student Innovation Challenge, regional hackathons, and a six-month Innovation Incubator.

To learn more about Xylem’s sustainability progress, download the 2022 Sustainability Report.

*Refers to cars powered by internal combustion engine.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye